Dimensional Fund Advisors LP Raises Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Dimensional Fund Advisors LP raised its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 19.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,036,743 shares of the company's stock after purchasing an additional 333,123 shares during the period. Dimensional Fund Advisors LP owned 1.54% of Organogenesis worth $5,702,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. raised its position in shares of Organogenesis by 309.3% during the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company's stock worth $11,136,000 after acquiring an additional 3,005,450 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Organogenesis during the 1st quarter worth approximately $1,846,000. Acadian Asset Management LLC lifted its position in shares of Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company's stock worth $8,521,000 after purchasing an additional 471,741 shares during the period. Wealth Dimensions Group Ltd. boosted its stake in shares of Organogenesis by 435.9% in the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company's stock valued at $1,142,000 after purchasing an additional 331,840 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in shares of Organogenesis by 102.8% during the first quarter. GSA Capital Partners LLP now owns 531,218 shares of the company's stock worth $1,509,000 after buying an additional 269,315 shares during the period. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Stock Up 1.0 %

ORGO traded up $0.03 during midday trading on Wednesday, hitting $3.02. The company had a trading volume of 308,387 shares, compared to its average volume of 859,695. The stock's 50 day moving average price is $2.76 and its 200 day moving average price is $2.75. Organogenesis Holdings Inc. has a 52 week low of $1.96 and a 52 week high of $4.70. The company has a market capitalization of $400.37 million, a price-to-earnings ratio of 75.50 and a beta of 1.60. The company has a quick ratio of 2.42, a current ratio of 2.73 and a debt-to-equity ratio of 0.22.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.11). The firm had revenue of $130.23 million during the quarter, compared to the consensus estimate of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. On average, research analysts anticipate that Organogenesis Holdings Inc. will post -0.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Lake Street Capital began coverage on Organogenesis in a report on Friday, June 28th. They set a "buy" rating and a $5.00 price target for the company.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.